165 results
Page 2 of 9
8-K
EX-99.1
ai3djxl2h
7 Dec 23
Regulation FD Disclosure
9:20am
8-K
EX-99.1
otzwe8
13 Nov 23
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.1
3m6jfjjf3env lvn
6 Nov 23
Departure of Directors or Certain Officers
8:20am
8-K
EX-99.1
369741q1fibjo ou0z
22 Sep 23
Regulation FD Disclosure
8:03am
8-K
EX-99.1
909j8npi4sk7xea5zr8
15 Sep 23
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
8:11am
8-K
EX-99.1
qog3eabrunb8w
9 Aug 23
NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:20pm
8-K
EX-99.1
31chf
3 Aug 23
NeuroBo Pharmaceuticals Receives First Site IRB Approval for its
8:15am
8-K
EX-99.1
0x0o92s40 2v
27 Jun 23
Other Events
8:26am
8-K
EX-99.1
d92uo
13 Jun 23
Other Events
8:25am
8-K
tlqq tg7dazz114zl
2 Jun 23
Other Events
4:19pm
8-K
EX-99.1
5bejfz1
12 May 23
Departure of Directors or Certain Officers
8:13am
8-K
EX-99.1
8gowolg
2 May 23
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH
8:18am
8-K
EX-99.1
ecu adggv6elu
3 Apr 23
NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH
8:14am
8-K
EX-99.1
snrmxqd
30 Mar 23
NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results
4:47pm